Ursodeoxycholic acid exacerbates peginterferon-induced interstitial pneumonia in a patient with hepatitis C.

about

Side effects of cytokines approved for therapy.

P2860

Q38255698-D50C091C-F2CF-483A-B5A5-6BB8B527AD39

P2860

Ursodeoxycholic acid exacerbates peginterferon-induced interstitial pneumonia in a patient with hepatitis C.

Item

http://www.wikidata.org/entity/Q44789725

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Ursodeoxycholic acid exacerbat ...... in a patient with hepatitis C.

@en

Ursodeoxycholic acid exacerbat ...... in a patient with hepatitis C.

@nl

type

Item

label

Ursodeoxycholic acid exacerbat ...... in a patient with hepatitis C.

@en

Ursodeoxycholic acid exacerbat ...... in a patient with hepatitis C.

@nl

prefLabel

Ursodeoxycholic acid exacerbat ...... in a patient with hepatitis C.

@en

Ursodeoxycholic acid exacerbat ...... in a patient with hepatitis C.

@nl

P1476

Ursodeoxycholic acid exacerbat ...... in a patient with hepatitis C.

@en

P2093

Masazumi Ogawa

http://www.w3.org/2001/XMLSchema#string

Motoki Nakagawa

http://www.w3.org/2001/XMLSchema#string

Rena Kaneko

http://www.w3.org/2001/XMLSchema#string

Satoshi Kamisago

http://www.w3.org/2001/XMLSchema#string

Satoshi Kusayanagi

http://www.w3.org/2001/XMLSchema#string

Tomoyuki Iwata

http://www.w3.org/2001/XMLSchema#string

Tomoyuki Umeda

http://www.w3.org/2001/XMLSchema#string

Yasuyoshi An

http://www.w3.org/2001/XMLSchema#string

Yuzuru Sato

http://www.w3.org/2001/XMLSchema#string

P2860

p53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis

Focal interstitial CC chemokine receptor 7 (CCR7) expression in idiopathic interstitial pneumonia.

Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis

Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis.

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma.

Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin.

Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS.

P2888

s12328-009-0075-y

P304

296-299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12328-009-0075-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26192429

http://www.w3.org/2001/XMLSchema#string

Ursodeoxycholic acid exacerbates peginterferon-induced interstitial pneumonia in a patient with hepatitis C.

about

P2860

P2860

Ursodeoxycholic acid exacerbates peginterferon-induced interstitial pneumonia in a patient with hepatitis C.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698